Thursday, October 29, 2026

KOREA’S PREEMPTIVE STRIKE : The $1.3 Billion Spy Ship Built To Kill Kim’s Submarine Threat Before It Even Starts

South Korea's Navy is advancing its AGX-III program to enhance maritime intelligence capabilities against threats like North Korean submarines.

Is South Korea’s Tungsten Mine the Key to Ending U.S. Dependence on China?

Yeongwol County's Sangdong tungsten mine is gaining global attention, with plans to enhance production and reduce dependency on China.

U.S. Cuts Section 232 Tariffs on Key Korean Industrial Machinery Exports to 15%

The U.S. reduces tariffs on South Korean machinery from 25% to 15%, impacting $2.3 billion in exports until 2027.

Jung Eun Kim

Author's Latest

Novo Nordisk’s Oral Wegovy Tops 3,000 Prescriptions in Its First Week—A Challenge to Injectable GLP-1s

Novo Nordisk's Wegovy oral treatment exceeds 3,000 prescriptions in its debut week, signaling a shift towards oral obesity medications.

From Hair Loss to Inflammation: JW Pharmaceutical Showcases Pipeline to Global Pharma at JPMorgan

JW Pharmaceutical participated in the JP Morgan Healthcare Conference, discussing potential drug partnerships and licensing deals.

Novo Nordisk’s Wegovy Pill Draws 3,000 Prescriptions in Its First Week—Is Oral GLP-1 Here to Stay?

Novo Nordisk's Wegovy oral obesity treatment saw over 3,000 prescriptions in its first week, indicating strong market demand.

JW Pharmaceutical Secures U.S. Patent for Hair Loss Drug Candidate JW0061

JW Pharmaceutical secures a U.S. patent for hair loss treatment JW0061, targeting GFRA1 receptor, ensuring market exclusivity until 2039.

2026: South Korea’s Advanced Regenerative Medicine R&D Investment Expands – What You Need to Know!

The Ministry of Health and Welfare aims to boost investments in advanced regenerative medicine R&D and improve research infrastructure in South Korea.

How MiniRin and Nokdernah Are Revolutionizing Nocturia Care for Seniors: A Comprehensive Guide

Hanmi Pharmaceutical and Ferring Korea partner to distribute Minirin and Nocdurna for nocturia treatment, enhancing patient access.

HLB’s Liragratinib: A Game-Changer in Cholangiocarcinoma Treatment Revealed at ASCO GI 2026!

HLB's lirafugratinib shows promise as a precision oncology drug, targeting FGFR2 in cancer treatment. FDA application expected soon.

The Easiest Way To Lose Investor Trust? Just Steal $6.7 Billion! BMS Masterclass In Bad Business

Bristol Myers Squibb faces a $6.7B lawsuit over alleged delays in drug approvals affecting former Celgene shareholders' payouts.

Chinese & Indian Medical Invasion: Pharmaceutic Dependency on Risk of Essential Medicine Supply

Concerns rise over South Korea's API industry reliance on China and India, with self-sufficiency at a record low of 25.6% in 2023.

Wegovy Gets Stronger: New Dose Promises Even More Weight Loss

Novo Nordisk's new high-dose Wegovy aims to enhance obesity treatment, with promising trial results and a strategic EU rollout planned.

Big Pharma Braces for $300 Billion Loss as Blockbuster Drug Patents Expire

Global pharma faces $300B losses from patent expirations, prompting a shift to multi-indication drugs and innovative therapies.

New Obesity Drug Shows Big Promise — and It’s Not from Eli Lilly or Novo

Metsera leads emerging obesity treatments with promising drug MET-233i, showing significant weight loss in trials, amid rising competition.

BIO USA 2025: Korea’s Pavilion Grows, Deals Multiply, and New Biotech Faces Emerge

BIO USA 2025 showcased South Korea's biotech presence, with significant participation from firms like Samsung Biologics and Lotte Biologics.

Samsung Launches New Mini-Organ Tech to Speed Up Cancer Drug Testing

Samsung Biologics launches Samsung Organoids for drug screening, focusing on anticancer candidates to enhance precision and reduce costs.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.